JPS6337085B2 - - Google Patents
Info
- Publication number
- JPS6337085B2 JPS6337085B2 JP54124593A JP12459379A JPS6337085B2 JP S6337085 B2 JPS6337085 B2 JP S6337085B2 JP 54124593 A JP54124593 A JP 54124593A JP 12459379 A JP12459379 A JP 12459379A JP S6337085 B2 JPS6337085 B2 JP S6337085B2
- Authority
- JP
- Japan
- Prior art keywords
- ginsenoside
- agent according
- antitumor agent
- main component
- antitumor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 229930182494 ginsenoside Natural products 0.000 claims description 49
- 229940089161 ginsenoside Drugs 0.000 claims description 45
- 229930182490 saponin Natural products 0.000 claims description 24
- 235000017709 saponins Nutrition 0.000 claims description 24
- 150000007949 saponins Chemical class 0.000 claims description 22
- 239000002246 antineoplastic agent Substances 0.000 claims description 16
- 235000008434 ginseng Nutrition 0.000 claims description 6
- 235000002789 Panax ginseng Nutrition 0.000 claims description 5
- 239000002904 solvent Substances 0.000 claims description 5
- 240000004371 Panax ginseng Species 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 2
- 238000010898 silica gel chromatography Methods 0.000 claims description 2
- 241000196324 Embryophyta Species 0.000 claims 1
- 239000008247 solid mixture Substances 0.000 claims 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 15
- 244000000626 Daucus carota Species 0.000 description 10
- 235000002767 Daucus carota Nutrition 0.000 description 10
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- 230000000259 anti-tumor effect Effects 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 230000000144 pharmacologic effect Effects 0.000 description 5
- 239000002994 raw material Substances 0.000 description 5
- 229930183217 Genin Natural products 0.000 description 4
- -1 diol saponins Chemical class 0.000 description 4
- 229930182470 glycoside Natural products 0.000 description 4
- 150000002338 glycosides Chemical class 0.000 description 4
- 241000208340 Araliaceae Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 3
- 235000003140 Panax quinquefolius Nutrition 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- XBZYWSMVVKYHQN-MYPRUECHSA-N (4as,6as,6br,8ar,9r,10s,12ar,12br,14bs)-10-hydroxy-2,2,6a,6b,9,12a-hexamethyl-9-[(sulfooxy)methyl]-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,12b,13,14b-icosahydropicene-4a-carboxylic acid Chemical compound C1C[C@H](O)[C@@](C)(COS(O)(=O)=O)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C XBZYWSMVVKYHQN-MYPRUECHSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- PVLHOJXLNBFHDX-XHJPDDKBSA-N Panaxadiol Chemical compound C[C@]1([C@H]2CC[C@@]3([C@@H]2[C@H](O)C[C@H]2[C@]3(CC[C@H]3C(C)(C)[C@@H](O)CC[C@@]32C)C)C)CCCC(C)(C)O1 PVLHOJXLNBFHDX-XHJPDDKBSA-N 0.000 description 2
- SYFJYASKXNAXKC-UHFFFAOYSA-N Panaxadiol Natural products CC1(C)CCCC(O1)C2CCC3(C)C2C(O)CC4C5(C)CCC(O)C(C)(C)C5CCC34C SYFJYASKXNAXKC-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 210000000601 blood cell Anatomy 0.000 description 2
- 244000309464 bull Species 0.000 description 2
- 229940008396 carrot extract Drugs 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 150000002009 diols Chemical group 0.000 description 2
- 230000002949 hemolytic effect Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 206010003445 Ascites Diseases 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- SRBFZHDQGSBBOR-HWQSCIPKSA-N L-arabinopyranose Chemical compound O[C@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-HWQSCIPKSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 102000043141 Nuclear RNA Human genes 0.000 description 1
- 108020003217 Nuclear RNA Proteins 0.000 description 1
- 235000002791 Panax Nutrition 0.000 description 1
- 241000208343 Panax Species 0.000 description 1
- QFJUYMMIBFBOJY-UXZRXANASA-N Panaxatriol Chemical compound C[C@]1([C@H]2CC[C@@]3([C@@H]2[C@H](O)C[C@H]2[C@]3(C[C@@H](O)[C@H]3C(C)(C)[C@@H](O)CC[C@@]32C)C)C)CCCC(C)(C)O1 QFJUYMMIBFBOJY-UXZRXANASA-N 0.000 description 1
- VIXIMKLMEZTTTC-UHFFFAOYSA-N Panaxatriol Natural products CC1(C)CCCC(O1)C2CCC3(C)C2C(O)CC4C5(C)CCC(O)C(C)(C)C5C(O)CC34C VIXIMKLMEZTTTC-UHFFFAOYSA-N 0.000 description 1
- 230000006819 RNA synthesis Effects 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- XSTXAVWGXDQKEL-UHFFFAOYSA-N Trichloroethylene Chemical compound ClC=C(Cl)Cl XSTXAVWGXDQKEL-UHFFFAOYSA-N 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 230000002929 anti-fatigue Effects 0.000 description 1
- 239000006286 aqueous extract Substances 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- DOAOYJIOTYDTNV-UHFFFAOYSA-N butan-1-ol;ethyl acetate;hydrate Chemical compound O.CCCCO.CCOC(C)=O DOAOYJIOTYDTNV-UHFFFAOYSA-N 0.000 description 1
- 230000009194 climbing Effects 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- OORMXZNMRWBSTK-UHFFFAOYSA-N dammaran Natural products C1CCC(C)(C)C2CCC3(C)C4(C)CCC(C(C)CCCC(C)C)C4CCC3C21C OORMXZNMRWBSTK-UHFFFAOYSA-N 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000000235 effect on cancer Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- YURJSTAIMNSZAE-HHNZYBFYSA-N ginsenoside Rg1 Chemical compound O([C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(C[C@@H]([C@H]4C(C)(C)[C@@H](O)CC[C@]4(C)[C@H]3C[C@H]2O)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C)(C)CC1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O YURJSTAIMNSZAE-HHNZYBFYSA-N 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 210000003405 ileum Anatomy 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 description 1
- 239000000401 methanolic extract Substances 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000009182 swimming Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 150000004072 triols Chemical group 0.000 description 1
Landscapes
- Saccharide Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Steroid Compounds (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP12459379A JPS5646817A (en) | 1979-09-27 | 1979-09-27 | Saponin antitumor agent |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP12459379A JPS5646817A (en) | 1979-09-27 | 1979-09-27 | Saponin antitumor agent |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS5646817A JPS5646817A (en) | 1981-04-28 |
| JPS6337085B2 true JPS6337085B2 (en, 2012) | 1988-07-22 |
Family
ID=14889285
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP12459379A Granted JPS5646817A (en) | 1979-09-27 | 1979-09-27 | Saponin antitumor agent |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS5646817A (en, 2012) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0344876U (en, 2012) * | 1989-09-12 | 1991-04-25 |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6222721A (ja) * | 1985-07-24 | 1987-01-30 | Noebia:Kk | 抗変異原性剤 |
| KR940000234B1 (ko) * | 1989-09-04 | 1994-01-12 | 김송배 | 신규 항암작용을 가지는 약학적 제제 및 제조방법 |
| DE10158281A1 (de) * | 2001-11-19 | 2003-05-28 | Mediwirk Gmbh | Pharmazeutisches Präparat |
| CN104383290A (zh) * | 2014-12-13 | 2015-03-04 | 李菲 | 早期食道癌扶正培本药剂及制备方法 |
-
1979
- 1979-09-27 JP JP12459379A patent/JPS5646817A/ja active Granted
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0344876U (en, 2012) * | 1989-09-12 | 1991-04-25 |
Also Published As
| Publication number | Publication date |
|---|---|
| JPS5646817A (en) | 1981-04-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Günther et al. | Quantitative determination of triterpenes in extracts and phytopreparations of Centella asiatica (L.) Urban | |
| DE2724947A1 (de) | Verfahren zur gewinnung eines ginsengextraktes und diesen enthaltende pharmazeutische zubereitungen | |
| Sabha et al. | Allium ursinum L.: bioassay-guided isolation and identification of a galactolipid and a phytosterol exerting antiaggregatory effects | |
| JPS6352013B2 (en, 2012) | ||
| CN105232891B (zh) | 延龄草提取物及其中皂苷类化合物的制备方法及其在制备抗缺血性心脏病药物中的应用 | |
| JPS6337085B2 (en, 2012) | ||
| NAMBA et al. | Hemolytic and its protective activity of ginseng saponins | |
| EP1131061B1 (de) | Prolaktin-senkendes mittel | |
| CN1833692B (zh) | 一种假马齿苋提取物及其制备方法和用途 | |
| KR100620107B1 (ko) | 진세노사이드 Ｒｇ2의 제조방법 | |
| Levine | Analysis of acetylsalicylic acid and acetylsalicylic acid tablets | |
| Abdel-Kader et al. | Effect of hydroxylated solvents on the active constituents of Salvadora persica root “Siwak” | |
| Miles et al. | Tumor inhibitors II: constituents and antitumor activity of Sarracenia flava | |
| Báthori et al. | New minor ecdysteroids from Silene otites (L.) Wib. | |
| CN110507662B (zh) | 一种黄精甾体皂苷元及其制备方法与应用 | |
| US5558866A (en) | Antineoplastic chemotherapeutic of plant origin, having high selectivity and greatly reduced toxicity, and process for the preparation thereof | |
| JPS58131999A (ja) | 抗腫瘍剤 | |
| CN112920146A (zh) | 倍半萜类化合物及其制备方法和在制备抗炎药物中的应用 | |
| KR100678490B1 (ko) | 파낙사디올과 파낙사트리올 분리방법 | |
| CN102295678A (zh) | 从太白银莲花提取的三萜皂苷类化合物的用途 | |
| Sowemimo et al. | Phytochemical investigation of Convolvulus arvensis (Convolvulaceae) | |
| EP2649991B1 (en) | Extracts and isolated compounds from Euphorbia granulata Forrsk. for treatment of ulcerative colitis | |
| JPH0471080B2 (en, 2012) | ||
| KR101237898B1 (ko) | 암 전이 억제용 조성물 | |
| JPH0469127B2 (en, 2012) |